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Introduction {#sec006}
============

Access to antiretroviral therapy has increased rapidly since 2005 and globally an estimated 21.7 million people are receiving antiretroviral therapy (ART) in which the World Health Organization (WHO) African Region accounts 60% \[[@pone.0227473.ref001]\]. In East and Southern Africa, the average adult ART coverage is 66% \[[@pone.0227473.ref002]\]. In Ethiopia, the overall ART coverage is 54% of which the adult ART coverage accounts 58% \[[@pone.0227473.ref003]\].

Antiretroviral therapy has significantly reduced mortality and improved the life expectancy of HIV infected patients but the success still critically depends on regular patient follow up \[[@pone.0227473.ref004]--[@pone.0227473.ref006]\]. The loss to follow-up (LTFU) among HIV infected patients is related to ART adherence and is becoming an increasing problem in sub-Saharan Africa as the ART program is expanding; this has resulted in a decrease in the clinician-to-patient ratio \[[@pone.0227473.ref007],[@pone.0227473.ref008]\]. It also accounts for the majority of all attrition and the problem of attrition can be addressed if one identifies the contributing factors and effectively tracks patients \[[@pone.0227473.ref006],[@pone.0227473.ref009]\].

According to a study done in one of the countries in Sub Saharan Africa, Uganda the proportion of LTFU is 24.6% \[[@pone.0227473.ref010]\]. According to different retrospective follow up studies done in Ethiopia the incidence rate of LTFU ranges from 8.2 to 11.6 per 100 person-years \[[@pone.0227473.ref011]--[@pone.0227473.ref013]\]. The proportion of LTFU is also different across different regions of Ethiopia. According to many studies in Ethiopia, the proportion of LTFU ranges from 11.5 to 26.7% \[[@pone.0227473.ref011],[@pone.0227473.ref013]--[@pone.0227473.ref016]\].

Loss to follow up of clients from ART have a great negative impact on the immunological benefits of ART, increase acquired immune deficiency syndrome (AIDS) related morbidity, mortality and hospitalization and it also results in serious consequences such as discontinuation of treatment, drug toxicity, treatment failure due to poor adherence and drug resistance \[[@pone.0227473.ref017]--[@pone.0227473.ref020]\]. Thus, High rates of LTFU from treatment programs pose a serious challenge to program implementers and constitutes an inefficient use of scarce treatment resources \[[@pone.0227473.ref021]\].

Different studies showed that LTFU is associated with base line sociodemographic factors like sex \[[@pone.0227473.ref010],[@pone.0227473.ref016],[@pone.0227473.ref022]--[@pone.0227473.ref024]\], age \[[@pone.0227473.ref010],[@pone.0227473.ref011],[@pone.0227473.ref013],[@pone.0227473.ref025],[@pone.0227473.ref026]\], educational status \[[@pone.0227473.ref026],[@pone.0227473.ref027]\], marital status \[[@pone.0227473.ref025],[@pone.0227473.ref028],[@pone.0227473.ref029]\], occupation \[[@pone.0227473.ref030],[@pone.0227473.ref031]\], disclosure status \[[@pone.0227473.ref016],[@pone.0227473.ref027]\], distance from the health facility \[[@pone.0227473.ref029]\], caregiver \[[@pone.0227473.ref032],[@pone.0227473.ref033]\] and clinical and treatment related factors like baseline WHO stage \[[@pone.0227473.ref025],[@pone.0227473.ref034]\], baseline CD4 count \[[@pone.0227473.ref013],[@pone.0227473.ref031],[@pone.0227473.ref035]\], history of opportunistic infection at enrollment \[[@pone.0227473.ref010]\], baseline functional status \[[@pone.0227473.ref015],[@pone.0227473.ref032],[@pone.0227473.ref035]--[@pone.0227473.ref037]\], opportunistic prophylaxis \[[@pone.0227473.ref011],[@pone.0227473.ref013],[@pone.0227473.ref014],[@pone.0227473.ref029]\] and type of ART regimen at start of their medication \[[@pone.0227473.ref023],[@pone.0227473.ref031]\].

Even though there are many studies done on LTFU and its predictors, valid estimates of incidence and predictors of loss to follow-up can be obtained if one considers death as a competing event (rather than counting those who died as censored) especially in poor clinical settings in which death is common and alters the probability of the occurrence of loss to follow up. However, in most of these studies death which is a competing risk of loss to follow up is often overlooked and this may produce misleading results. Therefore, this study aimed to estimate the incidence rate and to identify the predictors of LTFU by considering death as a competing event in University of Gondar Comprehensive Specialized Hospital, Northwest, Ethiopia.

Method {#sec007}
======

Study design and setting {#sec008}
------------------------

An institution-based retrospective follow-up study was conducted in University of Gondar Comprehensive Specialized Hospital between January 1, 2015, and December 31, 2018. The Hospital is found in Gondar town which is located 727 km from the capital city of the country, Addis Ababa and 172 km far from Bahir Dar, the capital city of the Amhara regional state. It is a leading referral hospital in Northwest Ethiopia serving more than five million people. ART service is one of the services given by this hospital and a summary of medical records of the hospital shows that currently, there are 5,573 patients on ART follow up among these 5,273 are adults.

Sample size determination and sampling method {#sec009}
---------------------------------------------

To check the sufficiency of samples, a minimum sample size (531) was determined using the power cox command of Stata 14 software. Record of study participants has been filtered first from the ART database according to their entry time to the follow-up, age and inclusion criteria. Finally, we select our study sample using a simple random sampling technique by R software.

Variable definitions and data collection procedures {#sec010}
---------------------------------------------------

The study population was all HIV-infected adults (age≥15 years) who enrolled at University of Gondar Comprehensive Specialized Hospital ART clinic and who had at least one follow-up visit between January 1, 2015, and December 31, 2018. Those patients who had unknown ART initiation date and transferred in with incomplete baseline data were excluded from the study. The primary outcome variable was loss to follow up (LTFU) defined as not taking ART refill for 3 months or longer from the last attendance for refill and not yet classified as dead or transferred-out \[[@pone.0227473.ref029]\]. The competing event was death which was defined as the death of a patient. A patient was classified as censored if he/she had a formally recorded transfer to another clinic or still on follow up at this hospital at the end of the study period. The predictor variables assessed were baseline socio-demographic factors (sex, age, marital status, educational status, occupation, residence, distance from health facility, disclosure status and caregiver) and baseline clinical and treatment-related factors (past opportunistic infection, baseline CD4 count, baseline functional status, type of regimen at start, isoniazid and cotrimoxazole preventive therapy, baseline and last known WHO clinical stage, viral load, BMI and current TB status). Here the functional was defined based on the ART guideline; Working: able to perform usual work inside or outside the home, Ambulatory: able to perform an activity of daily living, and bedridden: not able to perform an activity of daily living \[[@pone.0227473.ref038]\]. Disclosure in this study was defined as disclosure of the status that is being HIV positive to at least one individual. In addition, in this study caregiver was also defined as anyone who can support or assist the individual with HIV. The data were collected from the patient charts by one health officer and three clinical nurses by using a data extraction sheet which was designed based on study objectives. To control the data quality, training was given for the data collectors and the supervisor about the ways of extracting the data based on the study objectives. The tool was also pretested and the data were checked for consistency and completeness on a daily basis by the supervisor and principal investigator.

Data processing and analysis {#sec011}
----------------------------

The Data was entered using Epi-data version 3.1 and exported to Stata 14 and R 3.5.3 software for analysis. Descriptive statistics including proportions, median, tables, and charts was done to describe the characteristics of the study participants. Nonparametric estimation of cumulative incidence function (CIF) was done both graphically and using Gray's test. After fitting the model, the proportional sub distribution hazard assumption was also checked by using the plot of log (- log (1-CIF)) versus the log of time to failure for each covariate, by interacting each covariate with time and using Schoenfeld residual test. Bivariable competing regression analysis was fitted to identify factors associated with LTFU. Those variables with a p-value of \<0.2 in the bivariable analysis were again fitted to the multivariable competing risk regression analysis. Both crude and adjusted sub distribution hazard ratio with the corresponding 95% Confidence Interval (CI) was calculated to show the strength of association. In multivariable analysis, variables with a P-value of \<0.05 were considered statistically significant.

Ethical consideration {#sec012}
---------------------

Ethical approval was obtained from the Institutional Review Board of University of Gondar. Since this study used an analysis of secondary data from patient charts, we received a waiver for informed consent. To keep the confidentiality names and other personal identifiers were not included in the data collection tool.

Result {#sec013}
======

Baseline socio-demographic characteristics {#sec014}
------------------------------------------

A total of 531 HIV infected adults on ART were included in the final analysis. Of these, 303(57.4%), of participants were females. The median age of the study participants was 32 (IQR = 25--40) years. Nearly half 262 (49.34%) of the study participants had secondary and above educational status. Most 445(85.7%) of the study participants disclosed their HIV status to at least one person and 502(94.5%) of subjects had a caregiver ([Table 1](#pone.0227473.t001){ref-type="table"}).

10.1371/journal.pone.0227473.t001

###### Baseline socio-demographic characteristics for adult HIV positive patients on ART in University of Gondar Comprehensive Specialized Hospital between January 1, 2015, and December 31, 2018.

![](pone.0227473.t001){#pone.0227473.t001g}

  Variables             Category              Frequency   Percentage (%)
  --------------------- --------------------- ----------- ----------------
  Sex                   Female                303         57.44
  Male                  226                   42.56       
  Age(years)            15--30                249         46.89
  31--39                135                   25.42       
  ≥40                   147                   27.86       
  Marital status        Single                114         21.47
  Married               245                   46.14       
  Divorced              132                   24.86       
  Widowed               40                    7.53        
  Occupation            Employee              248         46.7
  Daily labor           75                    14.12       
  Other\*               208                   39.17       
  Religion              Orthodox              462         87.01
  Muslim                57                    10.73       
  Other\*\*             12                    2.26        
  Caregiver             Yes                   502         94.54
  No                    29                    5.46        
  Disclosure status     Disclosed             445         83.80
  Not disclosed         86                    16.20       
  Educational status    No formal education   128         24.11
  Primary education     141                   26.55       
  Secondary and above   262                   49.34       

Other\* = driver, house wife, jobless and student, other\*\* = protestant and catholic

Clinical and treatment-related characteristics {#sec015}
----------------------------------------------

Among the study subjects, 221 (41.62%) had baseline CD4 count ≤200 cell/mm3 with median baseline CD4 count of 250cell/mm3 (IQR = 110 to 429 cell/mm3). Based on the baseline WHO staging 238 (44.82%) of patients were stage I followed by stage III patients,119(22.41%). Most 374 (70.4%) of the participants had a working functional status and 473 (89.08%) of study participants were taking TDF-3TC-EFV at the start of their medication. Regarding prophylaxis against opportunistic infections, 236(87.45%) of the respondents were on co-trimoxazole Preventive Therapy (CPT) and 123 (23.16%) were on isoniazid preventive therapy (IPT) ([Table 2](#pone.0227473.t002){ref-type="table"}).

10.1371/journal.pone.0227473.t002

###### Clinical and treatment-related characteristics of adult HIV patients on ART at University of Gondar Comprehensive Specialized Hospital between January 1, 2015, and December 31, 2018.

![](pone.0227473.t002){#pone.0227473.t002g}

  Variable                     Category           Frequency   Percentage (%)
  ---------------------------- ------------------ ----------- ----------------
  Baseline CD4 count           ≤200               221         41.62
  201--350                     117                22.03       
  \>350                        193                36.35       
  Baseline WHO stage           Stage I            238         44.82
  Stage II                     101                19.02       
  Stage III                    119                22.41       
  Stage IV                     73                 13.75       
  Last known WHO stage         Stage I            301         56.69
  Stage II                     136                25.61       
  Stage III                    58                 10.92       
  Stage IV                     36                 6.78        
  Past OIs                     Yes                225         42.37
  No                           306                57.63       
  CPT                          Yes                366         68.93
  No                           165                31.07       
  IPT                          Yes                123         23.16
  No                           408                76.84       
  Baseline Functional status   Working            374         70.43
  Ambulatory                   121                22.79       
  Bedridden                    36                 6.78        
  Type of regimen at start     1e (TDF-3TC-EFV)   473         89.08
  1c (AZT-3TC-NVP)             39                 7.34        
  1d/1f/1g                     19                 3.58        
  Baseline BMI                 \<18.5             170         32.02
  18.5--24.9                   314                59.13       
  ≥25                          47                 8.85        
  Current TB status            Positive           30          5.65
  Negative                     501                94.35       

1d = AZT-3TC-EFV,1f = TDF-3TC-NVP,1g = ABC- 3TC-EFV, BMI = body mass index, OI = opportunistic infection, CPT = cotrimoxazole preventive therapy, IPT = isoniazid preventive therapy

Incidence of LTFU and death {#sec016}
---------------------------

Study subjects were followed for a median of 19.6 months (IQR: 8.4--34) after initiation of treatment with a total observation time of 935.75 person-years.

During the four years follow up period, 51(9.6%) were dead and 102(19.21%) had been LTFU ([Fig 1](#pone.0227473.g001){ref-type="fig"}). The overall incidence of death and LTFU were 5.4 (95% CI: 4.1--7.2), and 10.90 (95% CI: 8.9,13.2) per 100-person year respectively. Lost to follow up was highest in the first 12 months of ART follow up,15.1per100 person-year(95%CI:11.9,19.2).

![Proportion of survival status among adult HIV patients on ART in University of Gondar Comprehensive Specialized Hospital between January 1, 2015, and December 31, 2018.](pone.0227473.g001){#pone.0227473.g001}

Predictors of LTFU among adult HIV patients on ART {#sec017}
--------------------------------------------------

### Non-parametric estimation of cumulative incidence function of LTFU {#sec018}

Non parametrically, CIFs across groups were checked statistically using Gray's test (which is analogous to the log-rank test of normal survival analysis) and graphically by plotting each predictor variable against failure time.

Based on the result of the modified X^2^ test (Gray's test), there was a significant difference in CIF among categories of age, marital status, occupation, education, IPT, CPT, Functional status, disclosure status, baseline WHO stage, caregiver and type of regiment at the start of ART.

Graphically, belonging to the age group 15--30, being single, having an occupation other than that of an employee, not having caregiver, not taking IPT and CPT prophylaxis, being ambulatory, not having disclosed their HIV status, a baseline WHO stage IV, being on a regimen of AZT-3TC-NVP and not having a formal education were all risk factors for LTFU ([Fig 2](#pone.0227473.g002){ref-type="fig"}).

![Non-parametric estimates of cumulative incidence curves with LTFU (1) and death (2) as a competing event for selected variable categories of age, IPT, functional status, and disclosure.](pone.0227473.g002){#pone.0227473.g002}

### The multivariable competing risk regression model {#sec019}

After fitting a bivariable competing risk regression model all the predictor variables except sex and baseline CD4 count were found to have p-value \<0.2 and entered into multivariable analysis and variables such as age, occupation, regimen type at start, ambulatory functional status, IPT and CPT were found to be significant predictors for lost to follow up at 5% level of significance.

In our study keeping other variables constant, the sub hazard of LTFU is 2.01 times higher among adults whose age is between 15--30 years as compared to those whose age is ≥40 years (aSHR = 2.01; 95% CI: 1.11,3.63). Looking at occupation, the sub hazard of LTFU is 2.60 times higher among adults whose occupation is daily labor compared to those whose occupation is an employee (aSHR = 2.60; 95% CI: 1.45,4.66). Regarding CPT prophylaxis, the sub hazard of LTFU is 2.66 times higher among adults who are not taking CPT compared to their counterparts (aSHR = 2.66; 95% CI:1.68,4.21). The sub hazard of LTFU is 4.57 times higher among adults who are not taking IPT compared to their counterparts (aSHR = 4.57; 95% CI: 1.60,13.08). Keeping other variables constant, the sub hazard of LTFU is 2.1 times higher among adults who are taking regimen AZT-3TC-NVP compared to those taking TDF-3TC-EFV (aSHR = 2.10; 95% CI: 1.16,3.78). Moreover, the sub hazard of LTFU is 1.61 times among adults who have an ambulatory functional status at enrollment as compared to those who have a working functional status (aSHR = 1.61;95%CI:1.02,2.51) ([Table 3](#pone.0227473.t003){ref-type="table"}).

10.1371/journal.pone.0227473.t003

###### Bivariable and multivariable competing risk regression analysis for predictors of LTFU among adult HIV patients on ART at University of Gondar Comprehensive Specialized Hospital between January 1, 2015, and December 31, 2018.

![](pone.0227473.t003){#pone.0227473.t003g}

  Variable                    Category           Survival status   cSHR \[95% CI\]   aSHR \[95% CI\]                                                                
  --------------------------- ------------------ ----------------- ----------------- ------------------ ----------------------------------------------------------- --------------------------------------------------------
  Age (years)                 15--30             167               67                15                 2.85(1.63--4.98)                                            2.01(1.11--3.63) [\*](#t003fn002){ref-type="table-fn"}
  31--39                      103                20                12                1.35(0.69--2.65)   1.06(0.51--2.21)                                            
  ≥40                         108                15                24                1                  1                                                           
  Marital status              Single             67                38                9                  2.67(1.68--4.21)                                            1.51(0.90--2.53)
  Married                     192                35                18                1                  1                                                           
  Divorced                    92                 24                16                1.34(0.80--2.26)   1.14(0.65--2.02)                                            
  Widowed                     27                 5                 51                0.79(0.31--2.03)   0.77(0.30--1.97)                                            
  Occupation                  Employee           194               30                24                 1                                                           1
  Daily labor                 44                 26                5                 3.39(2.00--5.74)   2.60(1.45--4.66) [\*](#t003fn002){ref-type="table-fn"}      
  Other                       140                46                22                1.98(1.25--3.13)   1.38(0.81--2.33)                                            
  Educational level           No education       83                35                10                 1.74(1.12--2.69)                                            1.27(0.78--2.08)
  Primary education           104                20                17                0.78(0.46--1.32)   0.62(0.35--1.08)                                            
  Sec.& above                 191                47                24                1                  1                                                           
  Caregiver                   Yes                362               92                48                 1                                                           1
  No                          16                 10                3                 2.39(1.22--4.69)   1.05(0.45--2.46)                                            
  Disclosure                  Disclosed          334               71                40                 1                                                           1
  Not disclosed               44                 31                11                2.58(1.71--3.91)   1.56(0.92--2.58)                                            
  Past OIs                    Yes                240               51                34                 1                                                           1
  No                          238                51                17                0.72(0.49--1.07)   0.87(0.54--1.42)                                            
  CPT                         Yes                282               42                42                 1                                                           1
  No                          96                 63                9                 3.68(2.49--5.45)   2.66(1.68--4.21)[\*\*](#t003fn003){ref-type="table-fn"}     
  IPT                         Yes                110               4                 9                  1                                                           1
  No                          268                98                42                7.81(2.9--21.0)    4.57(1.60--13.08) [\*\*](#t003fn003){ref-type="table-fn"}   
  Functional status           Working            292               62                20                 1                                                           1
  Ambulatory                  71                 35                15                1.91(1.27--2.87)   1.61(1.02--2.51)[\*](#t003fn002){ref-type="table-fn"}       
  Bedridden                   15                 5                 16                0.87(0.35--2.17)   0.43(0.17--1.12)                                            
  Baseline WHO stage          Stage I/II         264               57                18                 1                                                           1
  Stage III                   77                 27                15                1.34(0.86--2.1)    1.17(0.67--2.04)                                            
  Stage IV                    37                 18                18                1.64(0.95--2.83)   1.58(0.78--3.20)                                            
  Last WHO stage              Stage I/II         362               79                16                 1                                                           1
  Stage III/IV                36                 23                35                1.47(0.91--2.36)   1.42(0.79--2.55)                                            
  Current TB status           Yes                12                9                 9                  1                                                           1
  No                          366                93                42                0.64(0.32--1.25)   1.36(0.56--3.29)                                            
  BMI                         \<18.5             111               41                18                 1.53(1.01--2.30)                                            1.14(0.71--1.83)
  18.5--24.9                  231                53                30                1                  1                                                           
  ≥25                         36                 8                 3                 0.94(0.45--1.97)   0.85(0.35--2.08)                                            
  Regimen type at the start   1e (TDF-3TC EFV)   348               82                43                 1                                                           1
  1c(AZT-3TC-NVP)             20                 15                4                 2.08(1.21--3.58)   2.10(1.16--3.78) [\*](#t003fn002){ref-type="table-fn"}      
  1d/1f/1g                    10                 5                 4                 1.26(0.52--3.07)   0.75(0.34--1.66)                                            

cSHR = crude sub hazard ratio, aSHR = adjusted sub hazard ratio,

\*pvalue\<0.05,

\*\*pvalue\<0.01,

1d = AZT-3TC-EFV,1f = TDF-3TC-NVP,1g = ABC- 3TC-EFV, BMI = body mass index

Discussion {#sec020}
==========

This study mainly assessed the incidence and predictors of LTFU among adult HIV patients on ART in University of Gondar Comprehensive Specialized Hospital, northwest Ethiopia. Many other studies reported different predictors for LTFU and our study also assessed socio-demographic, clinical and treatment-related factors. In our study factors such as age, occupation, history of taking IPT, CPT, baseline functional status and regimen type at ART initiation were found to be significantly associated with LTFU.

The incidence estimated in this study, which is10.90 per 100 person year, was consistent with studies done in different areas of Ethiopia \[[@pone.0227473.ref011],[@pone.0227473.ref013]\], South Africa \[[@pone.0227473.ref030]\] and Cameroon \[[@pone.0227473.ref029]\]. This might be due to the implementation of ART services according to the WHO ART guideline. However, it was lower than a study done in Asian-pacific \[[@pone.0227473.ref039]\]. This is because this study counts LTFU once for a single participant but there may be double or triple counting of patients who are LTFU since there may be reentering and re-LTFU and contribute to more than one episode of LTFU which increases the incidence (in case of Asian Pacific study). But it was higher than other studies done in Mekelle-Ethiopia \[[@pone.0227473.ref023]\], India \[[@pone.0227473.ref028]\] and Asia \[[@pone.0227473.ref040]\]. Lost to follow up in our study turned out to be higher than the study done in Mekelle might be due to the study period in which currently, starting from 2016, test and treat strategy is introduced in Ethiopia and this might increase the number of patients on follow up and which in turn increases self-referral to the other health facilities, as investigated by different studies \[[@pone.0227473.ref024],[@pone.0227473.ref041]\]. In addition, in search of literatures, patient satisfaction with healthcare system is associated with engagement in HIV care \[[@pone.0227473.ref032],[@pone.0227473.ref042]\], so there may be the difficulty of appropriate health service delivery and access since this hospital is a Comprehensive Specialized Hospital, which serves many patients and finally results in patient dissatisfaction and loss to follow up. Furthermore, the way operationalizing LTFU might be a reason for higher LTFU in our study as compared to studies in India and Asia because in our study LTFU is defined when a patient is lost for at least 90 days but in studies in India and Asia LTFU is defined when the patient is lost for at least 180 days.

The younger age groups were more likely to be LTFU in ART as compared to older patients. This result is congruent with different studies done in different regions of Ethiopia \[[@pone.0227473.ref011],[@pone.0227473.ref013]\], Nigeria \[[@pone.0227473.ref025]\], Sub Saharan Africa \[[@pone.0227473.ref010]\] and Guinea \[[@pone.0227473.ref026]\]. This finding might be because this group of population is either dependent on others or they are more mobile as compared to the older population and also in this study most of this group of the population had no caregiver which closely monitor their follow-up which finally may increase their tendency to LTFU. In addition, in this group of population there is fear of stigma and discrimination and due to this they preferred to enroll in care facilities located relatively far from their neighborhoods, they may be far away from this institution, and there may be additional costs in time and transportation which affects their regular follow up \[[@pone.0227473.ref031]\].

In our study patients whose occupation is daily labor increases the risk of LTFU and this is supported by a study done in the Oromia region of Ethiopia \[[@pone.0227473.ref031]\]. This might be since daily laborers pass the whole day in the workplace and do not have enough time to come to the health facilities for follow up. Because of the nature of their work, they are also more mobile and have no constant workplace that may end up with lost from follow up \[[@pone.0227473.ref043]\]. Besides, this group of population had low income (unable to feed themselves) and they believe that taking ART medication on an empty stomach is dangerous and finally this leads them to seek alternative healing options such as holy water by stopping ART and becomes lost to follow up \[[@pone.0227473.ref032],[@pone.0227473.ref044]\].

In the current study, those patients who were not taking IPT prophylaxis were at higher risk of LTFU. This finding is supported by different studies done in Ethiopia \[[@pone.0227473.ref011],[@pone.0227473.ref013],[@pone.0227473.ref014]\]. This might be due to, initiation of IPT which is recommended by the national ART guideline might directly or indirectly decrease LTFU by increasing retention of HIV patients on care since IPT prevents the occurrence of tuberculosis co-infection which is the most frequent life-threatening opportunistic disease among people living with HIV \[[@pone.0227473.ref038]\]. In addition, this might be because the most commonly mentioned factor motivating people to stay in care is improved health \[[@pone.0227473.ref032]\] and this might be happening through appropriate interventions such as management of opportunistic infections. Moreover, in this study patients who were not taking CPT were more likely to be LTFU from ART and this is in line with a study done in Cameroon \[[@pone.0227473.ref029]\]. This might be since CPT, given for the prevention of many opportunistic infections such as pneumocystis pneumonia, toxoplasmosis, bacterial infections & diarrheal diseases \[[@pone.0227473.ref038]\], might have a direct or indirect effect on retaining of patients on HIV care.

In this study, it was also found that ambulatory functional status at enrollment increases the risk of LTFU. This is in line with studies done in Ethiopia and Nigeria \[[@pone.0227473.ref035],[@pone.0227473.ref036]\]. This might be due to their inability to do their routine activity including their daily work and may become socially and economically disadvantageous and this may affect their stay in care. In contrast to other studies which showed that bedridden patients are associated with lost to follow up \[[@pone.0227473.ref015],[@pone.0227473.ref032]\], in this study being bed ridden patient is not associated with LTFU. This might be because of in this study there were small number of bedridden patients (very small sample size) which may result a biased statistical estimation.

Regimen type AZT-3TC-NVP during the starting of ART increases the risk of LTFU as compared to TDF-3TC-EFV. This is in line with a study done in Mekelle, Ethiopia \[[@pone.0227473.ref023]\]. This might be because AZT-3TC-NVP is taken twice per day (drug burden) that results in the patient not taking the drug appropriately and end up with LTFU and also TDF-3TC-EFV is fixed-dose combinations of ART agents which helps to reduce dosing complexity \[[@pone.0227473.ref045]\]. Tenofovir regimen is claimed to have a better safety profile, even though it may result renal toxicity, compared to zidovudine because of a reduced incidence of anemia and fat redistribution \[[@pone.0227473.ref046]--[@pone.0227473.ref050]\], so patients with AZT-3TC-NVP may have a loss of hope on the medication if they become ill due to anemia and other complications and finally may be lost from HIV care \[[@pone.0227473.ref032]\].

This study has some limitations. Since this study used baseline sociodemographic and clinical factors, there may be a change of these variables after a time but not properly recorded to include them in the analysis. This study was also conducted based on secondary data and full data on some potentially important predictors such as viral load, residence, and distance from the hospital were not available. For the differences noted between AZT and TDF regimen, the sample size for the AZT regimen was much smaller and may have provided a statistical bias that needs to be investigated further.

Conclusion {#sec021}
==========

In this study the incidence of LTFU was high. For investigating the predictor variables of LTFU, competing risk regression analysis was done considering death as competing event since the observation of death obscure the observation of LTFU. So, in this study after considering death as a competing event, patients on ART whose age was younger, not taking CPT prophylaxis, not taking IPT prophylaxis, being daily laborer, ambulatory functional status and being taking AZT-3TC-NVP medication at the start of ART were at higher risk for LTFU. Therefore, giving more attention and close follow up of these high-risk groups could decrease the rate of LTFU.

Supporting information {#sec022}
======================
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(XLS)
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Click here for additional data file.
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Dear Mr. Teshale,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process as shown in the two reviewer\'s comments.

We would appreciate receiving your revised manuscript by Jan 09 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.
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We look forward to receiving your revised manuscript.
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Matt A Price

Academic Editor
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Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.
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Please provide an amended Funding Statement that declares \*all\* the funding or sources of support received during this specific study (whether external or internal to your organization) as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>.  

Please state what role the funders took in the study.  If any authors received a salary from any of your funders, please state which authors and which funder. If the funders had no role, please state: \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

4\. Please include a caption for figure 2
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Please amend the statement in the conclusion to indicate that giving special attention to the high risk groups for loss to follow-up highlighted in this manuscript could decrease the rate of LTFU rather than stating it will decrease the rate of LTFU.

Please state the financial support received from the University of Gondar in the relevant financial disclosure section.

Line 60, amend to read \'Access to antiretroviral therapy has increased\...\'

Line 67, amend to read \'HIV infected patients\...\'

Line 68, correct to read \'as the ART program\...\'

Line 69, amend to \'\...is expanding; this has resulted in a decrease in the clinician-to-patient ratio.\'

Line 72, please clarify if the figure 24.6% is a proportion, prevalence or incidence rate. Please also clarify if this figure is representative of the entire region or if the study was conducted in specific country or part of the region.

Line 82 should read \'\...constitutes\...\'

Line 85, does this variable refer to the level of support from the caregiver?

Line 86; please correct the spelling of baseline.

Line 110, as the guidelines internationally have changed quite a lot over the past 5 years, please outline the eligibility criteria for initiation of ART and state how this changed during the duration of the study.

Line 131 should read \'\...daily basis\...\'

Line 155; please provide a definition for the variable disclosure. Was disclosure specific or did disclosure to at least 1 individual regardless of who they were qualify?

Line 156; please specify the definition of a caregiver in this context.

Line 161; please specify how you defined \'working functional status\'.

Line 262; Compared to working? Please provide the definition for \'working\' and \'ambulatory\' that you used in this study.

Line 162; please correct the statement to read \'\... were taking TDF-3TC-EFV at the start of their medication.\'

Line 162; consider amending the sentence to read \'Regarding prophylaxis against opportunistic infections\...\'

Line 182; based on table 1, should this read \'\...,having an occupation other than that of a government employee,\...\'? Should this statement include self-employed individuals as well?

Line 182; Please correct the grammar in this paragraph. Consider \'Graphically, belonging to the age group 15-30, being single, having an occupation other than that of a government employee, not having a caregiver, not taking IPT and CPT prophylaxis, being ambulatory, not having disclosed their HIV status, a baseline WHO stage IV, being on a regimen of AZT-3TC-NVP and not having a formal education were all risk factors for LTFU\'.

Line 186; this should read figure 2.

Line 222; Your study looked at data between 2015 and 2018, as you mention the possibility of the test and treat strategy having contributed to this, please clarify when the test and treat strategy was introduced in Ethiopia.

Please note that the study did not measure the contribution of workload at the clinic or the test and treat strategy on adherence to care and therefore it is out of place to state categorically in the conclusion that the test and treat strategy contributed to the higher rates of LTFU in your study.

Line 226; As the contribution of patient dissatisfaction was not measured in this study, please clarify that this will need to be measured in another study before a conclusion can be drawn on this.

Line 251; Please clarify how individual patients on IPT would note the benefits and better health outcomes from this intervention.

Are you implying that the the patients are well educated on the health benefits of IPT to the extent that it improved their adherence to ART?

Line 255; Please clarify what the national guideline on IPT and CPT was during the course of the study between 2015 and 2018. Were all patients offered the prophylactic drugs in equal measure to justify the conclusions you have drawn on motivation to remain on ART by those on prophylaxis?

Line 259; this sentence seems highly speculative and doesn\'t seem to be supported by the data in this paper.

Line 260; correct to read \'Holy water\'.

Line 264; This statement does not explain why no association was seen between being bedridden and LTFU.

Line 270; Consider comparing the safety profile of AZT regimens vs TDF regimen overall, ie. beyond anemia.

Under limitations of the study, for the differences noted between AZT and TDF regimen, please make a note that the sample size of the former was much smaller and may have provided a statistical bias that needs to be investigated further.

Please comment in the conclusion how the crude sub-hazard ratio was affected for the various variables by the competing risk analysis identifying mortality as a competing risk to LTFU.

Line 280 has an error; patients on TDF-3TC-EFV were less likely to be lost to follow-up than those on AZT-3TC-NVP.

Please make the correction.

Correct the title of Table 1 to read HIV positive patients.

Variables differ in table 1 and table 3. Under occupation, table 1 refers to government employee, self-employee, daily labor, housewife, jobless, and other while table 3 refers to employee, daily labor and others. Please reconcile the variables in these 2 tables.

Figure 2 is not visible and neither is the attachment.

Please correct the title of figure 2 as it currently reads figure 1.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Vincent Muturi-Kioi

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Editors' comments

When submitting your revision, we need you to address these additional requirements (issues related to journal requirements) and we addressed all the issues raised that is:-

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. So, based on the link what you have given we adjust our manuscript based on PLOS ONE\'s style.

2\. Regarding to questions raised about data availability and funding statement we amended and included in the revised cover letter.

3\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016, so the author created ORCID iD

4\. Please include a caption for figure 2, we checked and corrected (we added the caption) in the revised work.

Reviewers' comments and authors response

Dear reviewer, we would like to say thank you for the constructive comments given for the betterment of our paper. Here are the comments raised and the authors response.

1\. Please amend the statement in the conclusion to indicate that giving special attention to the high-risk groups for loss to follow-up highlighted in this manuscript could decrease the rate of LTFU rather than stating it will decrease the rate of LTFU.

Authors response; checked and Amended from ...giving special attention and close follow up of these high-risk groups will decrease the rate of LTFU...to ...giving special attention to the high-risk groups for lost to follow up highlighted in this study could decrease the rate of LTFU.

2\. Please state the financial support received from the University of Gondar in the relevant financial disclosure section.

Authors response; the funding statement is also commented above as a journal requirement and we include in the cover letter.

3\. Line 60, amend to read \'Access to antiretroviral therapy has increased\...\'

Authors response; checked and amended from '\...Antiretroviral therapy has increased rapidly...' to... 'Access to antiretroviral therapy has increased rapidly...' in the revised manuscript

4\. Line 67, amend to read \'HIV infected patients\...\'

Authors response; checked and amended from '.... Human Immune Deficiency Virus (HIV) infected patients...' to \'.... HIV infected patients\...'

5\. Line 68, correct to read \'as the ART program\...\'

Authors response; checked and corrected from 'ART program' to 'the ART program' the revised manuscript

6\. Line 69, amend to \'\...is expanding; this has resulted in a decrease in the clinician-to-patient ratio.\'

Authors response; Checked and Amended or modified from.... 'is expanding that results decreasing of clinician-to-patient ratio' to ... 'is expanding; this has resulted in a decrease in the clinician-to-patient ratio'.

7\. Line 72, please clarify if the figure 24.6% is a proportion, prevalence or incidence rate. Please also clarify if this figure is representative of the entire region or if the study was conducted in specific country or part of the region.

Authors response; Here the figure 24.6% is a proportion and this is representative of the specific country Uganda which is one of the countries in sub Saharan Africa. This is modified in the revised manuscript as ...'According to a study done in one of the countries in Sub Saharan Africa, Uganda the proportion of LTFU is 24.6 %'.

8\. Line 82 should read \'\...constitutes\...\'

Authors response; Checked and amended from '...constitute to '. \...constitutes\...' in the revised manuscript.

9\. Line 85, does this variable refer to the level of support from the caregiver?

Authors response; it means whether a patient has a care giver or not (yes/no), without considering the level of support, which is recorded as like this in ART intake form.

10\. Line 86; please correct the spelling of baseline.

Authors response; initially it was 'base line' but now in revised manuscript we correct the spelling into 'baseline'

11\. Line 110, as the guidelines internationally have changed quite a lot over the past 5 years, please outline the eligibility criteria for initiation of ART and state how this changed during the duration of the study.

Authors response; Even though the ART guide line changed quite a lot in the past five years, regarding the eligibility criteria for initiation of ART (now which is test and treat) as well. But in line 110 '.... from the ART database according to their entry time to the follow-up, age and eligibility criteria', when we say the eligibility criteria it is to mean inclusion criteria (to include those patients who had at least one follow up) and now it is amended for clarity in the revised manuscript as '....from the ART database according to their entry time to the follow-up, age and inclusion criteria'.

12\. Line 131 should read \'\...daily basis\...\'

Authors response; amended from '\...daily base\...' before to '\...daily basis\...' in the revised manuscript.

13\. Line 155; please provide a definition for the variable disclosure. Was disclosure specific or did disclosure to at least 1 individual regardless of who they were qualify?

Authors response; Disclosure in this study was to mean disclosure of the status that is being HIV positive to at least one individual regardless of who they were qualify (asked like .... 'Does anyone else know about your HIV status?' and recorded in the ART intake form). For clarity we added it in the method section in the revised manuscript.

14\. Line 156; please specify the definition of a caregiver in this context.

Authors response; in this study caregiver was defined as anyone who can support or give care to the individual with HIV and it was recorded as yes/no in the ART intake form. For clarity it is also stated in the method section in the revised manuscript.

15\. Line 161; please specify how you defined \'working functional status\'.

Line 262; Compared to working? Please provide the definition for \'working\' and \'ambulatory\' that you used in this study.

Authors response; The functional status was defined based on the ART guide line; Working: able to perform usual work inside or outside home, Ambulatory: able to perform activity of daily living. Bedridden: not able to perform activity of daily living and now in the revised manuscript it is stated in the method section.

16\. Line 162; please correct the statement to read \'\... were taking TDF-3TC-EFV at the start of their medication.\'

Authors response; We amended it ...'were taken TDF-3TC-EFV at the start of their medication' initially to '...were taking TDF-3TC-EFV at the start of their medication.\' In the revised manuscript.

17\. Line 162; consider amending the sentence to read \'Regarding prophylaxis against opportunistic infections\...\'

18\. Authors response; we checked the sentence and we modified '.... Regarding opportunistic prophylaxis' to \'Regarding prophylaxis against opportunistic infections\...\' in the revised manuscript.

19\. Line 182; based on table 1, should this read \'\..., having an occupation other than that of a government employee,\'? Should this statement include self-employed individuals as well? Authors response; Yes, this includes both government and self-employed patients. That is both governments employed and self-employed ... counted as employed

20\. Line 182; Please correct the grammar in this paragraph. Consider \'Graphically, belonging to the age group 15-30, being single, having an occupation other than that of a government employee, not having a caregiver, not taking IPT and CPT prophylaxis, being ambulatory, not having disclosed their HIV status, a baseline WHO stage IV, being on a regimen of AZT-3TC-NVP and not having a formal education were all risk factors for LTFU\'. Authors response; we reread it and we modified the original paragraph stating 'Graphically, being age group 15-30, being single, being occupation other than employee, being not having caregiver, not taking IPT and CPT prophylaxis, being ambulatory, those who have not disclosed their HIV status, being baseline WHO stage IV, being taking regiment type AZT-3TC-NVP and those who have no education were at higher risk of LTFU)' to 'Graphically, being age group 15-30, being single, being occupation other than employee, being not having caregiver, not taking IPT and CPT prophylaxis, being ambulatory, those who have not disclosed their HIV status, being baseline WHO stage IV, being taking regiment type AZT-3TC-NVP and those who have no education were at higher risk of LTFU' in the revised manuscript.

21\. Line 186; this should read figure 2.

Authors response; Checked and modified from saying figure 1 to figure 2 in the revised manuscript.

22\. Line 222; Your study looked at data between 2015 and 2018, as you mention the possibility of the test and treat strategy having contributed to this, please clarify when the test and treat strategy was introduced in Ethiopia.

Please note that the study did not measure the contribution of workload at the clinic or the test and treat strategy on adherence to care and therefore it is out of place to state categorically in the conclusion that the test and treat strategy contributed to the higher rates of LTFU in your study.

23\. Line 226; As the contribution of patient dissatisfaction was not measured in this study, please clarify that this will need to be measured in another study before a conclusion can be drawn on this.

Authors response; Based on the comments and issues raised for line 222 and 226 we write the justification accordingly like this '.... Lost to follow up in our study turned out to be higher than the study done in Mekelle might be due to the study period in which currently, starting from 2016, test and treat strategy is introduced in Ethiopia and this might increase the number of patients on follow up and which in turn increases self-referral to the other health facilities, as investigated by different studies. In addition, in search of literatures, patient satisfaction with healthcare system is associated with engagement in HIV care, so there may be the difficulty of appropriate health service delivery and access since this hospital is a Comprehensive Specialized Hospital, which serves many patients and finally results in patient dissatisfaction and loss to follow up. Furthermore, the way operationalizing LTFU might be a reason for higher LTFU in our study as compared to studies in India and Asia because in our study LTFU is defined when a patient is lost for at least 90 days but in studies in India and Asia LTFU is defined when the patient is lost for at least 180 days.'

24\. Line 251; Please clarify how individual patients on IPT would note the benefits and better health outcomes from this intervention.

Are you implying that the patients are well educated on the health benefits of IPT to the extent that it improved their adherence to ART?

Authors response; it is not to mean patients are well educated on the health benefits of IPT to the extent that it improved their adherence to ART but it is to mean taking IPT based on the recommendations of the national ART guideline prevent the most devastating and common illness among HIV patients which is Tuberculosis, so preventing tuberculosis improves the health as well makes the patient well.

25\. Line 255; Please clarify what the national guideline on IPT and CPT was during the course of the study between 2015 and 2018. Were all patients offered the prophylactic drugs in equal measure to justify the conclusions you have drawn on motivation to remain on ART by those on prophylaxis?

Authors response; all patients do not offered the prophylactic drugs, it depends on the patients profile that is IPT is administered at enrolment to HIV care after ruling out active TB but CPT is given for all clients any WHO stage and CD4 count \<=350 cells/mm3 Or WHO 3 or 4 irrespective of CD4 level. But many individuals expect burden of medication as a direct or indirect cause for discontinuing the medications and LTFU. So, our intention was to investigate this issue. In the revised manuscript we modify and re write the justification by considering the issues raised.

26\. Line 259; this sentence seems highly speculative and doesn\'t seem to be supported by the data in this paper and Line 260; correct to read \'Holy water\'.

Authors response; we amended the paragraph by removing unnecessary justifications and in the revised manuscript we removed the paragraph '..But if patients are not taking CPT, they are more vulnerable to many opportunistic infections and finally, they may be catchup with such diseases and either they may develop drug toxicity due to drug-drug interaction or they may prefer to go to Holly water by discontinuing such burden of drugs and finally end up with LTFU' and we re write the justification.

27\. Line 264; This statement does not explain why no association was seen between being bedridden and LTFU.

Authors response; Now it is explained in the main manuscript as 'In contrast to other studies which showed that bedridden patients are associated with lost to follow up, in this study being bed ridden patient is not associated with LTFU. This might be because of in this study there were small number of bedridden patients (very small sample size) which may result a biased statistical estimation.

28\. Line 270; Consider comparing the safety profile of AZT regimens vs TDF regimen overall, ie. beyond anemia.

Authors response; we try to adjust it to include the safety profile beyond anemia by searching different literatures. In the revised manuscript we rewrite it as '.....Tenofovir regimen is claimed to have a better safety profile, even though it may result renal toxicity, compared to zidovudine because of a reduced incidence of anemia and fat redistribution, so patients with AZT-3TC-NVP may have a loss of hope on the medication if they become ill due to anemia and other complications and finally may be lost from HIV care.'

29\. Under limitations of the study, for the differences noted between AZT and TDF regimen, please make a note that the sample size of the former was much smaller and may have provided a statistical bias that needs to be investigated further.

Authors response; As limitation, we indicated for the differences noted between AZT and TDF regimen, as '...the sample size for the AZT regimen was much smaller and may have provided a statistical bias that needs to be investigated further.'

30\. Please comment in the conclusion how the crude sub-hazard ratio was affected for the various variables by the competing risk analysis identifying mortality as a competing risk to LTFU.

Authors response; Based on the issues raised here we modified our conclusion as 'in this study the incidence of LTFU was high. For investigating the predictor variables of LTFU, competing risk regression analysis was done considering death as competing event since the observation of death obscure the observation of LTFU. So, in this study after considering death as a competing event, patients on ART whose age was younger, not taking CPT prophylaxis, not taking IPT prophylaxis, being daily laborer, ambulatory functional status and being taking AZT-3TC-NVP medication at the start of ART were at higher risk for LTFU. Therefore, giving more attention and close follow up of these high-risk groups could decrease the rate of LTFU.'

31\. Line 280 has an error; patients on TDF-3TC-EFV were less likely to be lost to follow-up than those on AZT-3TC-NVP. Please make the correction.

Authors response; we checked and we amended it as '.... those on AZT-3TC-NVP were at higher risk of LTFU.'

32\. Correct the title of Table 1 to read HIV positive patients.

Authors response; Checked and corrected in the revised manuscript

33\. Variables differ in table 1 and table 3. Under occupation, table 1 refers to government employee, self-employee, daily labor, housewife, jobless, and other while table 3 refers to employee, daily labor and others. Please reconcile the variables in these 2 tables.

Authors response; We were recategorized the variable occupation because of not fulfilling the chi square assumption for analysis but now we reconcile it by changing it in the descriptive part (Table1) in the revised manuscript.

34\. Figure 2 is not visible and neither is the attachment.

Authors response; Checked and corrected in the revised manuscript

35\. Please correct the title of figure 2 as it currently reads figure 1.

Authors response; Checked and corrected and now it reads figure 2
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Dear Dr. Teshale,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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Dear Dr. Teshale:
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